Azilect® is indicated for the treatment of idiopathic Parkinson’s disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end of dose fluctuations. Azilect® is an irreversible monoamine oxidase type B (MAO-B) inhibitor.1
Azilect® acts within the central nervous system, extending dopamine availability1,2
The Azilect® mode of action enhances levodopa therapy, reducing OFF time in patients recieving an optimised levodopa regimen.3
Azilect® (rasagiline) tablet contains 1mg rasagiline (as mesilate). For a full list of excipients, see Section 6.1. of the Summary of Product Characteristics.
The tablet is white to off-white, round, flat, bevelled tablets, debossed with “GIL” and “1” underneath on one side
and plain on the other side.1
Teva Pharma GmbH
Marketing Authorisation Number(s)
1 Azilect® (rasagiline) Summary of Product Characteristics.
2 Rascol O. Rasagiline in the pharmacotherapy of Parkinson’s disease- a review. Exp Opin Pharmacother 2005; 6(12): 2061-2075.
3 Elmer LW. Rasagiline adjunct therapy in patients with Parkinson’s disease: Post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013; 19(11): 930-936.
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession
because the materials included in this area of our website are specifically prepared for that audience
To understand why that is - please visit: Working in a regulated environment
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.